Slide 1

CorporatePresentationJ.B. Chemicals & Pharmaceuticals

www.jbcpl.com

CorporatePresentationJ. B Chemicals & Pharmaceuticals+91-22-30451200 | corporate@jbcpl.com www.jbcpl.com#J. B. Chemicals & Pharmaceuticals Ltd.Forward Looking StatementsIn this presentation we have disclosed forward looking information to enable investors to comprehend our prospects and take informed investment decisions. This presentation and other statements, written and oral, that we periodically make contain forward looking statements that set out anticipated results based on the managements plan and assumptions. We have tried wherever possible to identify such statements by using words such as anticipate, aims estimate, expects, project, intends, plans, believes, and words of similar substance in connection with any discussion of future performance. We cannot guarantee that these forward looking statements will be realized, although we believe we have been prudent in assumptions. The achievement of results is subject to risks, uncertainties and even inaccurate assumptions. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from those anticipated, estimated or projected. Everybody should bear this in mind.#J. B. Chemicals & Pharmaceuticals Ltd.#J. B. Chemicals & Pharmaceuticals Ltd.The name J. B. Chemicals & Pharmaceuticals Ltd. was christened after Mr. J. B. Mody who is the Chairman and founder of JBCPLJBCPL is a leading and publicly traded pharmaceutical company in IndiaLeading by the vision and dynamism of Mr. J. B. Mody, a visionary and pioneer with an experience of over five decades in the pharmaceutical industry, the group has diversified into different sectors

Background#J. B. Chemicals & Pharmaceuticals Ltd.Incorporated in 1976 with an IPO in 1985Listed on the BSE and NSE with a market cap of USD 110 million7 manufacturing sites in Gujarat and Maharashtra for formulations and API1 R&D centreSubsidiary in South Africa and RussiaTotal employee strength of 2900

Brief on JBCPL#J. B. Chemicals & Pharmaceuticals Ltd.Annual Revenues & Profits Rs. in crores

* Divestment of Russia-CIS OTC business to J&J #J. B. Chemicals & Pharmaceuticals Ltd.Annual Revenues & Profits USD in millions

* Divestment of Russia-CIS OTC business to J&J #J. B. Chemicals & Pharmaceuticals Ltd.Strategic Business Units#J. B. Chemicals & Pharmaceuticals Ltd.IndiaPrescription productsDomestic market estimated at about USD 11 billion and growing by about 18% as per ORG

JBCPL Ranked 36th (ORG) with 3 brands featuring in top 300 brands reported by ORG

JBCPL continued consolidation process during 2011-12, and adopted key brands focus marketing strategy.

#J. B. Chemicals & Pharmaceuticals Ltd.IndiaTop 4 therapeutic segments: Gastro-enterology, Cardiovascular, Pain management and Antibiotic

Acute segment contributes about 82% of total sales

Current field force: 1100 sales representatives#J. B. Chemicals & Pharmaceuticals Ltd.IndiaGrowth PlanJBCPL has placed increased concentration on domestic market for next level growth.Increase in field forceNew product introductions JBCPL plans to increase field force to 1500 in 2012-13. This is aimed at strengthening rural market presence with strength increase in urban market too

#J. B. Chemicals & Pharmaceuticals Ltd.Contrast Media niche focusContrast Media ProductsCaters to niche radio-diagnostic products used in CT Scan, MRI and Cath Lab through 30 sales representativesIopamidolIohexolGadopentetate dimeglumineDiatrizoate MeglumineIn-licensed a new Ultrasound Contrast Imagining product (Definity) of Lantheus Medical Imaging Inc. from USA

#J. B. Chemicals & Pharmaceuticals Ltd.Russia/Ukraine/CIS

KazakhstanKyrghyztanUzbekistanTajikistanTurkmenistanAzerbaijanArmeniaGeorgia MaldovaUkraineByelorussiaLithuaniaLatviaEstoniaRussiaMongolia#J. B. Chemicals & Pharmaceuticals Ltd.Russia/Ukraine/CISRussia is one of the most potential marketsRussian market is estimated to be about US $12 billion at retail level, growing by about 7% in value annuallyJBCPL is ranked amongst the top Indian companiesEntered Russia in 1992 Offices in Russia/Ukraine and some CIS countries

#J. B. Chemicals & Pharmaceuticals Ltd.Russia/Ukraine/CISDivested OTC portfolio to Johnson & Johnson in May 2011Contract manufacturing for J&J for these OTC productsPrescription business continues through wholly owned subsidiary in Russia#J. B. Chemicals & Pharmaceuticals Ltd.Global Contract Manufacturing and Product pipeline will increase to fuel growth

Activity wise breakup#J. B. Chemicals & Pharmaceuticals Ltd.Global

Top markets breakup#J. B. Chemicals & Pharmaceuticals Ltd.South AfricaIn 2007, JBCPL has made strategic investment in Biotech Laboratories (Pty) Ltd., South Africa, a BEE marketing and sales, marketing and distribution companyHave 49% equity stake with preference shares to take it to 51%Robust products pipeline to strengthen direct business with Biotech#J. B. Chemicals & Pharmaceuticals Ltd.Contract Manufacturing (Clear Focus)

Projects awarded by multinationals globallyMore than 10 clientsTailor made services for customers

Contract Manufacturing#J. B. Chemicals & Pharmaceuticals Ltd.Complete packageNew Product developmentAnalytics servicesTechnology transferRegulatory supportManufacturing

Contract Manufacturing#J. B. Chemicals & Pharmaceuticals Ltd.Lozenges, a JBCPL niche strength, has excellent scope in global marketMedicated and HerbalWe manufacture lozenges under our own brands and private labelPrivate label lozenges for leading UK/EU, South African, Australian and Canadian companies.

Lozenges#J. B. Chemicals & Pharmaceuticals Ltd.JBCPL manufactures 2 APIsone of the largest manufacturer of Diclofenac Sodium (BP, EP, USP) and Nifedipine

API Business#J. B. Chemicals & Pharmaceuticals Ltd.Brands | AssetsZecuf herbalCough and ColdNicardia (Nifedipine)Anti-hypertensiveMetrogyl (Metronidazole)AnaerobicideRantac (Ranitidine)Anti-peptic ulcerantPanum (Pantaprazole)Anti-peptic ulcerantOF (Ofloxacin)AntibioticDicloran (Diclofenac Sodium)NSAID#J. B. Chemicals & Pharmaceuticals Ltd.At DamanLocated at Kadaiya, DamanManufactures lozenges and tabletsLozenges approved by:UK MHRATGA AustraliaMCC South AfricaFDB GhanaManufacturing Facilities

#J. B. Chemicals & Pharmaceuticals Ltd.At GujaratPlant TI 10Located at PanoliManufactures tabletsFacility approved byUS FDAUK MHRATGA AustraliaMCC South AfricaINVIMA ColombiaGermany (EU-GMP)

Manufacturing Facilities#J. B. Chemicals & Pharmaceuticals Ltd.At GujaratPlant IV -17 Located at PanoliManufactures injectables - FFS, vials and ampoulesFacility approved by:MCC South AfricaINVIMA Colombia

Manufacturing Facilities

#J. B. Chemicals & Pharmaceuticals Ltd.At GujaratPlant IV -14 Located at PanoliManufactures injectables, ointments & cold rubsFacility approved by: MCC South AfricaNDA UgandaPharmacy Board TanzaniaINVIMA ColombiaManufacturing Facilities

#J. B. Chemicals & Pharmaceuticals Ltd.At GujaratPlant L-6Located at PanoliManufactures herbal liquidsManufacturing Facilities

#J. B. Chemicals & Pharmaceuticals Ltd.At GujaratPlant D 9Located at PanoliManufactures Diclofenac APIFacility approved by:US FDA Germany EU-GMPManufacturing Facilities

#J. B. Chemicals & Pharmaceuticals Ltd.At GujaratPlant UM 12Located at AnkleshwarManufactures tablets and liquidsFacility approved by:NDA - Uganda (Tablets & liquids)Pharmacy Board - Tanzania (liquid)Manufacturing Facilities#J. B. Chemicals & Pharmaceuticals Ltd.StrategyANDA: Develop and manufacture products for USA marketContract Manufacturing: Increase our customer base by providing quality products at cost effective pricesRussia marketing: Form JV/Partnerships for marketing New Territories: Expand into newer territories through partnershipsCapacities: Enhance capacities in 2012-13 for ANDA and contract manufacturingtabletsInjectablesLozenges

#J. B. Chemicals & Pharmaceuticals Ltd.

Thank YouJ. B Chemicals & Pharmaceuticals+91-22-30451200 | corporate@jbcpl.comwww.jbcpl.com

#J. B. Chemicals & Pharmaceuticals Ltd.Chart17236707866367910111847

2008-092009-102010-112011-12*

Sheet12008-092009-102010-112011-12*Sales723670786636PAT7910111847

Chart11621711871291726.431.19.4

2008-092009-102010-112011-12*

Sheet12008-092009-102010-112011-12*Sales162171187129PAT1726.431.19.4

Chart1935551

SalesOTC5%Branded generics40%Contrast Media5%ANDA/ Contract manufacturing50%

Sheet1SalesOTC9Ethicals35Hospitals & Contrast Media5Contract Manufacturing51

Chart1141325324138

SalesUSA/Canada21%South Africa10%Africa20%Australia6%South-east Asia22%Middle east/Gulf11%Latin America10%

Sheet1SalesUSA/Canada14South Africa13Rest of Africa25Australia3South-east Asia24Middle east/Gulf13Latin America8To update the chart, enter data into this table. The data is automatically saved in the chart.